Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases

Cells. 2022 Dec 16;11(24):4102. doi: 10.3390/cells11244102.

Abstract

The endocannabinoid system has been shown to be involved in various skin functions, such as melanogenesis and the maintenance of redox balance in skin cells exposed to UV radiation, as well as barrier functions, sebaceous gland activity, wound healing and the skin's immune response. In addition to the potential use of cannabinoids in the treatment and prevention of skin cancer, cannabinoid compounds and derivatives are of interest as potential systemic and topical applications for the treatment of various inflammatory, fibrotic and pruritic skin conditions. In this context, cannabinoid compounds have been successfully tested as a therapeutic option for the treatment of androgenetic alopecia, atopic and seborrhoeic dermatitis, dermatomyositis, asteatotic and atopic eczema, uraemic pruritis, scalp psoriasis, systemic sclerosis and venous leg ulcers. This review provides an insight into the current literature on cannabinoid compounds as potential medicines for the treatment of skin diseases.

Keywords: allergic contact dermatitis; atopic dermatitis; cannabinoid receptors; cannabinoids; dermatomyositis; endocannabinoid system; fibrosis; inflammation; pruritus; psoriasis; systemic sclerosis; wound healing.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cannabinoids* / pharmacology
  • Cannabinoids* / therapeutic use
  • Humans
  • Pruritus
  • Skin
  • Skin Diseases* / drug therapy
  • Skin Neoplasms* / drug therapy

Substances

  • Cannabinoids

Grants and funding

This research received no external funding.